Summary
This Nature Reviews Urology article examines the mechanisms underlying resistance to second-generation androgen receptor antagonists in advanced prostate cancer. As suggested by the 2021 publication date and journal scope, the review synthesises evidence on molecular and clinical drivers of treatment failure, including androgen receptor mutations, altered receptor expression, and activation of bypass signalling pathways. The work appears intended to inform clinical understanding of disease progression and potential therapeutic strategies in castration-resistant prostate cancer.
UK applicability
Findings on androgen receptor antagonist resistance are directly relevant to UK clinical oncology and urology practice, as enzalutamide and abiraterone are approved treatments within the NHS for castration-resistant prostate cancer. Understanding resistance mechanisms may inform treatment sequencing and patient stratification in UK cancer centres.
Key measures
Treatment resistance phenotypes, androgen receptor mutations, alternative signalling pathways, progression-free survival outcomes
Outcomes reported
The study examined mechanisms of resistance to second-generation androgen receptor antagonists (enzalutamide, abiraterone) in patients with castration-resistant prostate cancer. It likely reviewed clinical and molecular evidence for treatment failure and disease progression.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.